Table 4.
Survival of HRA and THA, the reference group. Endpoint was defined as revision of any component for any reason. Survival rates were obtained from the Kaplan-Meier analysis
| A | B | C | D | E | F | G | H | I | J | |
|---|---|---|---|---|---|---|---|---|---|---|
| BHR | 1,856 | 4.4 (0.0–9.0) | 1,253 | 97 (96–98) | 668 | 96 (95–97) | 111 | 95 (94–97) | 0.72 (0.56–0.94) | 0.02 |
| ASR | 995 | 3.1 (0.3–5.8) | 440 | 95 (93–97) | 39 | 92 (89–95) | – | – | 1.28 (0.95–1.73) | 0.1 |
| ReCap | 657 | 2.5 (0.4–5.7) | 190 | 96 (94–98) | 18 | – | – | – | 0.94 (0.59–1.48) | 0.8 |
| Conserve Plus | 469 | 2.1 (0.4–4.7) | 65 | 97 (95–98) | – | – | – | – | 1.05 (0.61–1.83) | 0.9 |
| Durom | 333 | 3.2 (0.2–5.1) | 144 | 96 (94–98) | 1 | – | – | – | 1.03 (0.60–1.74) | 0.9 |
| Corin (Cormet) | 91 | 5.6 (0.2–7.6) | 87 | 96 (92–100) | 52 | 92 (86–99) | 5 | – | 1.11 (0.50–2.48) | 0.8 |
| All HRAs | 4,401 | 3.5 (0.0–9.0) | 2,177 | 96 (96–97) | 777 | 94 (93–95) | 115 | 94 (93–95) | 0.93 (0.78–1.10) | 0.4 |
| All THAs | 48,409 | 3.9 (0.0–9.0) | 25,482 | 96 (96–97) | 14,607 | 95 (95–96) | 5,601 | 94 (94–95) | 1.0 | – |
A n
B Mean follow-up (years)
C At risk, 4-year
D 4-year survival (95% CI)
E At risk, 6-year
F 6-year survival (95% CI)
G At risk, 8-year
H 8-year survival (95% CI)
I Adjusted risk ratio (RR) for revision (95% CI) from the Cox regression analysis (HRAs compared to THAs; with adjustment made for age, sex, diagnosis, and implant).
J p-value